Ind-Swift Laboratories Reports Strong Q2 FY27 Results Driven by Formulations Shift
Ind-Swift Laboratories Ltd · Press Release · 30 Oct 2026, 11:21 pm
Ind-Swift Laboratories Reports Strong Q2 FY27 Results Driven by Formulations Shift Ind-Swift Laboratories reported robust standalone Q2 FY27 performance, with operating income growing 50.15% YoY to ₹234.89 crore and operating EBITDA surging nearly 5x YoY to ₹42.33 crore, expanding margins by 1,256 bps YoY to 18.02%. PAT rose 3.54x YoY to ₹31.03 crore with a 13.21% margin. Sequentially, revenue and operating EBITDA grew 26.23% and 27.02% QoQ, respectively. Growth was driven by operational scaling in finished dosage formulations, expanding CDMO partnerships, and raw material cost efficiencies, supported by a net-debt-free balance sheet.
Original exchange filing (PDF)
More announcements from Ind-Swift Laboratories Ltd
- Please find enclosed transcript for earnings call held on November 04, 2026. · 10 Nov 2026
- Audio recording of earning conference call held on 04.11.2026 on un-audited financial results for the quarter ended 30.09.2026. · 05 Nov 2026
- Please find enclosed investor presentation on un-audited financial results for the quarter ended September 30, 2026 · 04 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of receipt of funds raised through preferential issue of 70,00,000 Fully Convertible Warrants · 03 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of funds raised through Preferential Issue 2.6 Cr Fully Convertible Warrants · 03 Nov 2026
- Please find enclosed Schedule of Analyst / Investor Meet which will be held on Wednesday, November 04, 2026, at 04.00 P.M. IST in respect of financial results of the Company for the quarter .... · 04 Nov 2026
- Please refer attached pdf · 30 Oct 2026
- Please refer attached pdf · 30 Oct 2026
